Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval for a new indication from the National Medical Products Administration (NMPA) for its Botox (botulinum toxin type A) product. The drug is now approved for the temporary improvement of significant or very significant masseter muscle protrusion, commonly referred to as hypertrophy, in adult patients.
Botox, a well-established brand in the aesthetics and therapeutic markets, initially received approval in the US in 1989 for the treatment of adult eyelid spasms and strabismus. It later expanded its indications to include the treatment of glabellar lines in 2002, marking a significant milestone in the cosmetic use of the product.- Flcube.com
